(NASDAQ: WVE) Wave Life Sciences's forecast annual revenue growth rate of -9.39% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Wave Life Sciences's revenue in 2024 is $113,305,000.On average, 4 Wall Street analysts forecast WVE's revenue for 2024 to be $9,729,537,520, with the lowest WVE revenue forecast at $5,448,981,234, and the highest WVE revenue forecast at $12,069,444,519. On average, 4 Wall Street analysts forecast WVE's revenue for 2025 to be $7,488,680,672, with the lowest WVE revenue forecast at $3,790,808,309, and the highest WVE revenue forecast at $12,027,867,912.
In 2026, WVE is forecast to generate $11,655,268,141 in revenue, with the lowest revenue forecast at $5,662,978,477 and the highest revenue forecast at $18,700,913,377.